Now that even Sinclair has RT’d ketamine slowing epigenetic aging…
There are potential arylcyclohexylamines/“dissociatives” that are even more effective. MXE is one (hard to source now, but synthesis may become easier later)
[other examples include O-PCE, Mxipr, FXE, etc]. I have noticed that they are often more popular than traditional psychedelics, esp b/c they are less likely to be scheduled and way more tolerable/lucid than traditional psychedelics (much less likely to make people “crazy” than non-DMT psychedelics).
They are very experimental so there is always “experimental risk”, but if I were to make a guess, I would think that many (esp MXE/methoxetamine) are less risky than ketamine. Also, them being mostly unknown makes the chances of a “very positive outcome” to one more likely than more known compounds.
Also, their level of experimentalness (and the reluctance of risk-averse drug companies to touch them) means that the ROI of investigating them on rowansci or orchestra-research or other agent platforms might be high-ROI
And since Bryan Johnson has gone after 5-MeO-DMT, maybe methoxetamine is gonna be next! It does seem to induce increases in wellness esp b/c you can take it more often than ketamine.
" ToolUniverse to make Claude more powerful for scientific discovery. Zitnik Lab And ToolUniverse is an ecosystem of 600+ scientific tools spanning drug discovery, genomics, proteomics — molecular docking predictors, literature retrieval APIs, Python-based modeling, statistical analyses" => maybe put methoxetamine there